---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-122129"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T09:18:10.000293+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies receives Nasdaq bid price deficiency notice; board changes announced

## Summary
- Received Nasdaq notice on April 25, 2023 for minimum bid price below $1.00 for 30 consecutive days.
- Has 180 days until October 23, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not cured, may transfer to Nasdaq Capital Market for additional 180-day grace period; failure could lead to delisting.
- Director Kathleen Reape resigned effective Nov 1, 2023 due to employer guidelines; Board to appoint successor.
- Board reconstituted with six directors; Reape moves from Class III to Class I to allow shareholder vote in 2024.

## SEC filing metadata
- accession: 0001193125-23-122129
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/0001193125-23-122129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/d406158d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-122129
- JSON: https://secwatch.observer/filing/0001193125-23-122129.json
- Plain text: https://secwatch.observer/filing/0001193125-23-122129.txt

## Key facts
- Listing & Compliance Notices
  Taysha Gene Therapies, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: April 25, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 23, 2023, to regain compliance with the minimum bid price requirement. To regai
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/0001193125-23-122129-index.htm
- Executive change
  Kathleen Reape was appointed as Class I Director at Taysha Gene Therapies, Inc..
  - Action: appointed as Class I director
  - Role: Class I Director
  source text: Effective immediately prior to the conclusion of the 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”), the Company expects that Dr. Reape will resign as a Class III director of the Company. Upon her resignation, the Board intends to appoint Dr. Reape as a Class I director of the Company to serve until the 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/0001193125-23-122129-index.htm
- Executive change
  Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: Director
  source text: Kathleen Reape provided notice to the board of directors (the “ Board ”) of the Company of her decision to resign from the Board, effective November 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523122129/0001193125-23-122129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.